Digestive Diseases Center "Gastro"

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials

Phase

• Phase 33 trials

Status

• Completed2 trials
• Active, not recruiting1 trial

Lead sponsor

• Eli Lilly and Company3 trials

Running trials

• Active, not recruiting

  A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

  NCT03519945· Phase 3· Eli Lilly and Company· Source

Closed trials

• Completed

  A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT03524092· Phase 3· Eli Lilly and Company· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source